Blog post
IMF Myeloma Support Groups, Down with Dex Research, and Defining Cure in MyelomaScope and MethodologyThis article summarizes educational presentations and discussions from Day 1 of the International Myeloma Foundation (IMF) Patient & Family Seminar held in Boca Raton, Florida. The content…
Blog post
A summary of some notable key multiple myeloma research from April-May 2026 Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from April-May 2026…
News Article
Rural Barriers to Myeloma Care Patients need access to expert care regardless of where they liveBy Danielle Doheny, IMF Director, Public Policy & Advocacy When my father was diagnosed with myeloma, our family quickly learned that one of the most important factors in…
Blog post
Shining a Light on Scientists’ Vital Work in Multiple Myeloma CareThis blog was written by IMF Support Group Leader and multiple myeloma patient Terry Glassman.I’ve been a multiple myeloma patient for almost three and a half years now. Myeloma is a complex and nuanced disease; because of that, we…
Blog post
Based on Data from Pivotal Myeloma Clinical Trials, The Amazing New “Normal” in Myeloma Is Here for Today’s Patients By Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO IMF Medical Advisor Scope and Methodology StatementThis article was…
Blog post
Key Takeaways from the Facebook Live Q&A: Dr. Sagar Lonial Answers Your Myeloma Questions Dr. Sagar Lonial, a member of the IMF Scientific Advisory Board and the IMF International Myeloma Working Group, answers myeloma questions in a summary of the Facebook Live held on March 25, 2026.Dr.…
Blog post
A summary of some notable key multiple myeloma research from March-April 2026 Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals March-April 2026. Content was…
News Article
CHMP recommends expanding the use of melflufen — to include patients with disease progression after at least two prior lines of therapy, and those with lenalidomide-refractory myeloma. On Thursday, September 17, the Committee for Medicinal Products for Human Use (CHMP) of the European…
Blog post
AI Is Already Shaping Healthcare, But How Are People Actually Using It? According to the article, “The Future of Healthcare: AI, Public Health and the Digital Revolution,”…
Blog post
Drs. Joseph Mikhael and Melissa Alsina Answer Myeloma Questions — a Summary of the March 14, 2026, Facebook Live On Saturday, March 14, IMF Medical Advisor Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, along with associate professor of medicine in the Blood and Marrow Transplant Program at…
Blog post
From Early Warning Signs to a 14-Year Watch-and-WaitThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling stories will…
Blog post
IMF Director of Public Policy & Advocacy Danielle Doheny breaks down barriers to care and the reasons why the International Myeloma Foundation’s (IMF) Advocacy Team is actively working to ensure timely, affordable, and equitable access for all patients. By Danielle Doheny…
Event
REGISTER NOW October 25th, 20263:30 PM – 6:30 PM ET Venue: Tree of Life Christian Center & MinistriesLocation:16321 NW 47th Avenue Miami Gardens, FL 33054 Sign In and…
Page
A summary report from the 2026 GMAN Annual Meeting, which took place in person from June 5–7, 2026, in Stockholm, SwedenThe International Myeloma Foundation’s (IMF) 2026 Global Myeloma Action Network Summit took place from June 5-7, 2026, in Stockholm, Sweden — convening leaders from more than 40…
IMF Person
Hello,My name is Khyre Edwards; I am the new Manager of Grassroots Advocacy at the International Myeloma Foundation! I have worked in advocacy and organizing in some capacity for the last 20 years and am excited to bring those skills and experience here. I attended the University of South Florida…
Blog post
A summary of some notable key multiple myeloma research from February-March 2026 Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals February-March 2026.…
Videos
So You're MRD Negative: Does That Mean Your Myeloma Is Gone? | Myeloma in a MinuteYou've been told you're MRD negative. Does that mean there's no myeloma left? In this Myeloma in a Minute video, IMF Medical Advisor Dr. Joseph Mikhael explains what minimal residual disease (MRD) means, how MRD…
Blog post
Shifting Perspectives After a Multiple Myeloma DiagnosisThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling stories will…
Blog post
Show the world that you are #MoreThanMyeloma this 2026 Myeloma Action Month! Light the world red and participate in month-long IMF events this March. This year, the International Myeloma Foundation (IMF) is inviting the global myeloma community to demonstrate the spirit of #…
Blog post
The 2025 IMF Latin American Myeloma Network (LAMN) Master Class and Summit took place on November 14–15, 2025, in Santiago, Chile. By Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO IMF Chief Medical Officer …
Blog post
A summary of some notable key multiple myeloma research from January-February 2026Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from January-February 2026. Content was…
News Article
IMF Advocates Move a Step Closer to Making Oral Chemotherapy Affordable in the U.S. On September 15, 2026, the U.S. House Committee on Oversight and Government Reform’s Subcommittee on Health Care and Financial Services held a hearing on “Unequal Treatment: Addressing the Drivers of…
Blog post
One Patient Hopes His Voice Will Raise Overall Myeloma AwarenessThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling…
Blog post
Best of ASH 2025: IMF Chief Medical Officer Dr. Joseph Mikhael’s Top 10 Multiple Myeloma Abstracts By Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO IMF Chief Medical Officer …
Blog post
ASCO’s Updated Living Guideline for Multiple Myeloma: FAQs and Key Updates Scope and Methodology This week’s blog answers frequently asked questions (FAQs) about the recently published updated living guideline on the treatment of multiple myeloma — a…
Blog post
A summary of some notable key multiple myeloma research from December 2025 to January 2026 Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from December 2025 -…
Blog post
Finding Meaning in the American Society of Hematology Annual Meeting & ExpositionI start with a heartfelt thank you to the IMF for bringing the patients to science so we can bring the science to the patients!When I first attended American Society of Hematology (ASH) Annual Meeting &…
Blog post
ASH 2025 Multiple Myeloma Updates: What the Latest Research Means for Patients and Care Partners Scope and Methodology This week’s blog summarizes key takeaways from the Top Myeloma Research Presented at ASH 2025: Easy-to-Understand Insights for Patients…
Blog post
Multiple Myeloma Patient and Support Group Co-Leader Diane Phipps Shares Her Perspective on the Myeloma Community A Diagnosis and a Turning PointIn an interview with the International Myeloma Foundation (IMF), Diane Phipps shared something she has come to believe deeply about living with…
Blog post
ASH 2025 Multiple Myeloma Breakthroughs: Key Trial ResultsScope and Methodology This week’s blog summarizes breakthrough myeloma abstracts presented by IMF Scientific Advisory Board (SAB) and International Myeloma Working Group (IMWG) members at the 67th American Society…
Blog post
Multiple Myeloma Treatment Advances at ASH 2025: A Patient’s TakeBy Jim Shoemaker #1 Abstract Title: Enhanced efficacy of TRAIL or TRAIL-CD28 chimera armored anti-BCMA CAR T cells in multiple myeloma.I want to begin by saying this plainly: I am not in the…
Blog post
A summary of some notable key multiple myeloma research from November-December 2025 Scope and MethodologyThis week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from November-…
Blog post
MGUS and Smoldering Myeloma at ASH 2025: What’s NewBy Jessie Daw, PhDThe 2025 American Society of Hematology (ASH) meeting moved fast, and attending virtually didn’t slow the pace. As a virtual member of the International Myeloma Foundation’s (IMF) Myeloma Voices team, I was busy,…
Blog post
Dr. Shaji Kumar on Smoldering Myeloma, High-Risk Disease & What’s Next Scope and Methodology This week’s blog summarizes the top takeaways from a recent Q&A interview with IMF Scientific Advisory Board Member and IMWG Member Dr. Shaji Kumar (Mayo Clinic —…
Blog post
Faster Myeloma Progress: ASH 2025 Takeaways on CAR-T and New DrugsBy Jill Zitzewitz, PhD The day before the American Society of Hematology (ASH) meeting kicks off each year is Satellite Symposia Day, where community oncologists can attend and receive continuing education…
Blog post
ASH 2025 Myeloma Satellite Symposium: SMM, Quad Therapy & SDMBy Jessie Daw, PhDI was up and at’em for my first session, which began at 6:30AM Central time. This session, Steady Progress in Multiple Myeloma: Applying New Data and Updated Guidelines Throughout Treatment, looked…
Blog post
IMS 2025 Highlights in Multiple Myeloma Treatment The 22nd International Myeloma Society (IMS) Annual Meeting was held from September 17–20, 2025 in Toronto, Canada. By Dr. Joseph Mikhael IMF Chief Medical Officer Scope and MethodologyThis…
Blog post
October and November 2025: What’s New in Myeloma? At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage,…
Blog post
Key Takeaways from the 2025 IMWG, ASCO, and EHA ConferencesEvery year, three annual events take place in quick succession — ASCO, IMWG, and EHA. These highly-anticipated meetings hold special significance for researchers and clinicians working in the field of myeloma. By Dr. Joseph MikhaelIMF…
Blog post
Myeloma and Health Equity: One Patient’s Fight for Better CareThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. …
Page
2026 Susie Novis Durie Grant Recipients One of the ways the IMF's Global Myeloma Action Network® (GMAN®) accomplishes its mission is by awarding Susie Novis Durie (SND) Educational Grants to patient advocacy organizations to elevate their work. Here are the 2026 SND Grant Recipients:Argentina…
Blog post
2025 Iceland Cycling Expedition: Riding to End Multiple MyelomaFrom August 27 – September 2, a team of 20 iron-willed individuals — myeloma patients, care partners, doctors, researchers, and industry partners alike — embarked on another unforgettable 150-mile cycling expedition of Iceland’s…
Blog post
"The ongoing care for myeloma is a marathon, not a sprint. And all throughout, resilience will, undoubtedly, need to be enhanced." — IMF Co-Founder Dr. Brian G.M. Durie (1942-2025)
As a fitting tribute to Dr. Brian G.M. Durie — a highly-esteemed pioneer in myeloma…
Blog post
2025 Myeloma Policy Updates: Medicare $2,000 Cap, Parity & Medicaid Access An informative discussion with International Myeloma Foundation (IMF) Director of Public Policy and Advocacy Danielle Doheny on U.S. policy updates, Medicare cap, drug parity, telehealth and other relevant issues…
Blog post
MGUS & Smoldering Myeloma in 2025: iStopMM Screening and Risk Updates The iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study in…
Blog post
At the end of each month, the International Myeloma Foundation (IMF) brings you some of the latest and most relevant news (myeloma research, clinical trials, treatments, drug authorizations, and more) to give a renewed sense of hope, courage, and resilience to the myeloma community. …
Blog post
An informative conversation between IMF Chief Medical Officer Dr. Joseph Mikhael and IMF Scientific Advisory Board Member Dr. Shaji Kumar on what myeloma patients and their families should expect next in terms of early screening and diagnosis, treatments, and care.
On the second…
Blog post
Myeloma Misdiagnosis to CAR-T Remission: A Survivor’s Advocacy StoryThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling…
Videos
Your Multiple Myeloma Questions Answered: Neuropathy, GLP-1s, Treatment Decisions & More What are patients asking about multiple myeloma, CAR T therapy, bispecific antibodies, treatment side effects, and more? In this Q&A, IMF Nurse Leadership Board…